Isracann announces to enter into MoU for European distribution
Category: #business  By Mateen Dalal  Date: 2020-01-02
  • share
  • Twitter
  • Facebook
  • LinkedIn

Isracann announces to enter into MoU for European distribution

Isracann Biosciences, Inc., an Israel-based specialty pharmaceutical company, announced that it has entered into a Memorandum of Understanding (MoU) for a distribution agreement to serve major legalized cannabis markets in Europe. The name of partner distributor has not been disclosed yet.

The anonymous distributor has conditionally entered into an MoU with Isracann due to commercial realism. As a part of the agreement, the distributor will help the company towards strategic export and leveraging opportunities. The principal proposal of the agreement is to offer a non-binding alternative on dried flower products depending upon export laws in Israel and minimum quantity, quality, and time of delivery.

The proposed distributor signifies that both the partners will import the product through the Republic of Malta, in accordance with jurisdictional transshipment and importation regulations. The distributor affirms its plan to use the product of Isracann as raw input for value-added handling, extraction, packing, branding, and export distribution.

Under the agreement, the unnamed distributor will build a regional processing facility to satisfy European Union Good Manufacturing Practice (EU-GMP). The EU has specified these standards to implement them as a regulatory need for medicinal products.

Darryl Jones, CEO, Isracann, reportedly stated that the company realized that it has a requirement for strategic distribution agreements before beginning its agriculture endeavor in Israel. The company selected Malta owing to its positive business environment, outstanding logistics, and proximity to key European markets, he further added.

Isracann had earlier declared Germany as its target to enter into the EU markets, which is pending due to Israeli export licensing approval. In March 2017, Germany had legalized medical cannabis and has emerged as the major medical cannabis market in Europe. The country is likely to grow considerably over the next years due to the presence of a potential patient base of more than 1 million.
 

Source links:

https://www.globenewswire.com/news-release/2020/01/02/1965510/0/en/Isracann-Enters-MOU-for-European-Distribution.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

AstraZeneca to present results of Farxiga’s DAPA-CKD trial at ESC 2020
AstraZeneca to present results of Farxiga’s DAPA-CKD trial at ESC 2020
By Mateen Dalal

According to reliable sources, British-Swedish multinational pharmaceutical company AstraZeneca plc will present the much awaited results of the Phase III DAPA-CKD trial of Farxiga in CKD (chronic kidney disease) at ESC Congress 2020. Sources with r...

FDA grants Emergency Use Authorization to Abbott’s COVID-19 antigen
FDA grants Emergency Use Authorization to Abbott’s COVID-19 antigen
By Mateen Dalal

Abbott Laboratories, a U.S.-based medical devices and healthcare firm, has reportedly received the Emergency Use Authorization (EUA) from the U.S. FDA (Food and Drug Administration) for the detecting COVID-19 virus with its portable antigen test Bina...

Hyundai Wia Corp. signs gun parts export contract with BAE Systems
Hyundai Wia Corp. signs gun parts export contract with BAE Systems
By Mateen Dalal

Hyundai Wia Corp., a South Korea-based defense firm, has reportedly signed gun parts export contract with BAE Systems plc of worth USD 100 million via a pre-value accumulation system. As per the agreement, Hyundai Wia will supply over 106 types of gu...